Hamilton, Bermuda; 4. November 2013-Rezgen5 Limited, a company listed on the Bermuda Stock Exchange under the symbol REZG5.BH, announced today that it is actively seeking portable alternatives for a second listing on a major global stock exchange. RezGen5 previously listed on the Berlin Stock Exchange. However, this listing was discontinued after the company's primary dealer withdrew from marketmaking at several secondary quotes.
Stuart Garret, founder and CEO of RezGen5, said: "I am extremely confident that we will soon find a suitable stock exchange for a secondary listing of our shares. We are currently weighing several options to best meet the needs of our investors. "Mr. Garret added," We continue to improve our scientific model and work tirelessly to commercialize our anti-aging molecule to business to promote the company. "
About RezGen5 Limited
RezGen5 Limited is a Bermuda-based biopharmaceutical company focused on the discovery and development of proprietary, orally available, small molecule medicines that have potential for the treatment of age-related diseases, including metabolic diseases such as type 2 diabetes, Alzheimer's and heart Have cycle diseases. Rezeng 5 is dedicated to improving people's quality of life by empowering people to do more, feel better, and live longer. The company is headquartered in Devonshire, Bermuda. For more information about the Company, including a copy of this news release and details of the Company's current development products, please visit www.Rezgen5.com.
Cautionary statement regarding forward-looking statements
The Company advises investors that any forward-looking statements or forecasts made by the Company, including those in this news release, are subject to risks and uncertainties that could cause the Company's actual results to differ materially from those anticipated. The factors that could affect the Company's operations are listed on the Company's Web site under the "Risk Factors" heading in the "Business Review" section.
This news release does not constitute an offer to buy or solicitation to buy or sell the shares of RezGen5 Limited.
Investors and shareholders are urged to read each of these documents as they become available.
Investors and Shareholders may also request free copies of these documents by contacting the Investor Relations Department of RezGen5 Limited.
Contact: ppgad@pucrs.br
No liability is assumed for the accuracy of the translation! Please note english original message!
The original English message can be found at:
http://www.irw-press.at/press_html.aspx?messageID=29197
